Advisors Asset Management, Inc.
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1297376
Monument, CO
Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$11,374
-$6,078 QoQ
Shares Held
567
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Advisors Asset Management, Inc. holds $38,396,219 across 40 Biotechnology names. LYEL ranks #40 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
24,300 | $10,850,922 | |
| 2 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
177,703 | $4,399,926 | |
| 3 | ASND |
Ascendis Pharma A/S
|
12,200 | $2,790,506 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,085 | $2,383,594 | |
| 5 | INCY |
Incyte Corp
|
21,594 | $2,032,427 | |
| 6 | ARQT |
Arcutis Biotherapeutics, Inc.
|
79,116 | $1,863,972 | |
| 7 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
18,718 | $1,627,904 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
6,948 | $1,387,168 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,374 | 567 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $17,452 | 567 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $9,208 | 567 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $5,083 | 575 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||